Protein marker combination for screening clinical ineffective recanalization of great vascular occlusion stroke and application of protein marker combination
A protein marker combination of GUCA2A, CCL14, STAB1, and VSIG4, identified via proteomics, effectively predicts ineffective recanalization in LVO-AIS, enhancing treatment strategies and reducing economic burden through accurate peripheral blood detection.
Patent Information
- Application Number
- CN202411118826.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-15
AI Technical Summary
Current methods lack accurate early prediction indicators for clinically ineffective recanalization in large vessel occlusive stroke (LVO-AIS), leading to high economic burden and poor patient outcomes despite reperfusion therapies.
A protein marker combination comprising GUCA2A, CCL14, STAB1, and VSIG4, identified through high-throughput proteomics, is used to predict ineffective recanalization by detecting their expression levels in peripheral blood samples, facilitating individualized treatment strategies.
The protein marker combination provides a high diagnostic accuracy of 0.959 in distinguishing ineffective recanalization, offering a reliable tool for clinical decision-making and reducing the economic burden.
Smart Images

Figure CN119064590A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine and molecular biology, and specifically relates to a protein marker combination for screening clinically ineffective recanalization of large vessel occlusive cerebral stroke and its application. Background Art
[0002] Acute ischemic stroke (AIS) accounts for about 85% of all strokes and is the second leading cause of preventable death worldwide. It can cause permanent disability and death and has become a global public health problem. About 46% of AIS cases are caused by acute intracranial large vessel occlusion (LVO). Reperfusion therapy (intravenous thrombolysis, endovascular treatment (EVT)) is the key to the treatment of AIS. EVT greatly reduces the mortality rate of large vessel occlusive cerebral infarction and improves the prognosis of AIS. However, despite the timely and successful recanalization of the occluded blood vessels, nearly half of the LVO-AIS patients who received EVT still have poor functional recovery. This phenomenon is called "futile recanalization (FR)". Numerous meta-analyses suggest that factors such as advanced age, high NIHSS score, delayed EVT treatment, multiple mechanical thrombectomy attempts, preoperative comorbidities (hypertension, diabetes), elevated blood sugar, collateral compensation status, and IL-6 levels are associated with an increased risk of FR, which can predict the occurrence of FR and help make decisions on EVT selection. The incidence of FR can be reduced by improving patients' treatment options, shortening recanalization time, reducing the number of endovascular treatment attempts, and improving postoperative blood pressure and blood sugar management. However, in clinical practice, multiple factors interact and are difficult to control, often leading to a rapid deterioration of the patient's condition or even death, seriously affecting the early control and functional rehabilitation of stroke patients, and bringing a heavy economic burden to families and society. This has become a major clinical problem that needs to be solved in the current field of cerebrovascular disease. Therefore, accurate preoperative prediction of FR provides a theoretical basis for the selection of treatment strategies for patients, but there is currently a lack of accurate early prediction indicators for FR. Therefore, exploring early specific early warning diagnostic factors for FR can provide individualized and accurate diagnosis and treatment for the selection of EVT treatment options.
[0003] To date, the pathophysiological mechanism of FR is still unclear. Several studies have found that the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, matrix metalloproteinase-9, tenascin-C, thioredoxin, ADAMTS13, and gelsolin are independently associated with FR. A cohort study found that patients who achieved recanalization 2 hours after intravenous thrombolysis showed higher baseline ADAMTS13 activity than those who did not. For patients undergoing EVT, ADAMTS13 < 982 ng / mL was an independent predictor of FR. However, the relationship between blood biomarkers as a practical tool and the pathophysiological mechanism of FR has not been fully studied.
[0004] As the executor of life activities, changes in protein abundance and function can directly reflect the collective physiological or pathological state. Proteomics can study the common protein composition, function and interaction in a certain type of cell or tissue through high-throughput technology, and can provide a biological explanation for the pathological changes of FR. Therefore, establishing an early screening model for protein markers based on proteomics, identifying and detecting peripheral blood protein biomarkers of FR patients at baseline, will help early screening of FR patients and provide individualized diagnosis and treatment plan decisions.
[0005] A proteomic study of jugular venous blood from patients with anterior circulation LVO-AIS before and after successful recanalization by EVT found that 13 differentially expressed proteins were identified before EVT treatment and 23 differentially expressed proteins were identified after EVT treatment in the effective recanalization (ER) and FR groups, which were involved in protein degradation and folding, adipogenesis or atherosclerosis, inflammatory response, maintenance of blood-brain barrier integrity, angiogenesis and cell-cell adhesion, autophagy, neuroendocrine secretion, electrolyte homeostasis, vesicle traffic, glucose metabolism, redox reaction, and cell growth / proliferation, migration or apoptosis. Proteomic studies may help to gain a deeper understanding of the mechanism of FR and can provide molecular markers for early prediction of FR, providing a theoretical basis for effective guidance of treatment strategies. However, there is currently a lack of screening tests for FR. Therefore, finding new molecular markers is of great significance for early screening of FR, timely warning, and effective improvement of individualized treatment strategies.
[0006] In summary, intravenous thrombolysis and EVT are the key to vascular recanalization. For LVO-AIS patients who meet the tissue time window, EVT treatment can be performed. Even patients with large core infarction areas can reduce the degree of disability. However, EVT treatment is expensive, and about 50% of patients have FR. However, there are currently no definite biological markers or imaging markers to predict the occurrence of FR, which has brought a huge economic burden to patients and society. Summary of the invention
[0007] In view of the deficiencies of the prior art, the present invention provides a protein marker combination for screening clinically ineffective recanalization of large vessel occlusive stroke and its application. The biological markers that can predict FR are screened out through high-throughput proteomics, which can effectively predict the occurrence of FR, provide an individualized solution for the selection of LVO-AIS treatment strategy, and significantly reduce the economic burden on patients.
[0008] The present invention is achieved through the following technical solutions:
[0009] A protein marker combination for screening clinically ineffective recanalization in large vessel occlusive stroke, wherein the protein marker combination includes GUCA2A, CCL14, STAB1 and VSIG4.
[0010] The application of the above protein marker combination in the preparation of a product for screening clinically ineffective recanalization of large vessel occlusive stroke.
[0011] Preferably, the product comprises a reagent or a kit for specifically detecting the expression amount of the protein marker combination in a sample.
[0012] Preferably, the sample is peripheral blood of a subject.
[0013] Preferably, the reagents include human GUCA2A, CCL14, STAB1 and VSIG protein capture antibodies.
[0014] A kit for screening clinically ineffective recanalization of large vessel occlusive stroke comprises a detection reagent, wherein the detection reagent comprises human GUCA2A, CCL14, STAB1 and VSIG protein capture antibodies.
[0015] Preferably, the kit is an ELISA detection kit.
[0016] Use of the above protein marker combination in the preparation of a product for diagnosing the prognosis of LVO-AIS patients.
[0017] Preferably, the product comprises a reagent or a kit for detecting the expression amount of the protein marker combination by ELISA.
[0018] The beneficial effects of the present invention are as follows:
[0019] (1) The detection sample of the present invention is the patient's peripheral blood. Peripheral blood specimens are easy to obtain, which saves time and effort for patients with acute cerebral infarction where time is of the essence, and provides a strong theoretical basis for the diagnosis and treatment decisions of patients.
[0020] (2) The present invention develops a new protein marker combination for FR screening and diagnosis, providing a new reference for FR screening.
[0021] (3) The protein marker combination of the present invention has a high combined diagnostic value. ROC curve analysis shows that it can better distinguish and screen FR patients, with an area under the curve of 0.959. It has good sensitivity and specificity and is expected to become an important indicator for the clinical diagnosis and treatment of FR. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 Proteomic analysis of the expression of GUCA2A (A), CCL14 (B), STAB1 (C), and VSIG4 (D) in ER and FR groups (N ER =5,N FR =5);
[0023] Figure 2 To verify the expression of GUCA2A (A), CCL14 (B), STAB1 (C) and VSIG4 (D) in ER and FR groups (N ER =80,N FR =80);
[0024] Figure 3 The ROC curve was used to analyze the combined diagnostic performance of GUCA2A, CCL14, STAB1 and VSIG4. DETAILED DESCRIPTION
[0025] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0026] Unless otherwise specified, the technical means used in the following examples are all conventional means well known to those skilled in the art, and the experimental methods without specifying the specific conditions are all conventional methods in the art.
[0027] Example 1
[0028] In the early stage of this example, FR screening was performed, and 5 pairs of plasma from patients with FR and ER were selected from patients undergoing EVT treatment for LVO-AIS. The changes in the protein spectrum of peripheral blood plasma specimens were analyzed by 4D-DIA quantitative proteomics technology to screen differentially expressed proteins. Finally, four protein molecules were selected, including guanylate cyclase activator 2A (GUCA2A), chemokine (C-Cmotif) ligand 14 (CCL14), stablin-1 (STAB1), and V-set and immunoglobulin domain containing4 (VSIG4). Subsequent verification was performed by expanding the sample size, combined with statistical analysis, for the screening of FR. The specific method steps are as follows:
[0029] 1. Research subjects and samples
[0030] A total of 60 patients with LVO-AIS who underwent EVT and successfully recanalized and were admitted to Nanjing First Hospital from January 2021 to June 2023 were selected. All patients were diagnosed by two neurologists independently performing clinical scale scoring and imaging examinations. During the baseline period, 3-5 mL of human peripheral blood was obtained using EDTA anticoagulant tubes, and plasma was separated by centrifugation within 30 minutes after collection and stored in a -80℃ refrigerator.
[0031] 2. According to the NIHSS score and mRS score 24 hours after recanalization, the patients were divided into ER group and FR group (NIHSS score decreased by <4 points and mRS score >2 points 24 hours after recanalization), including 80 ER patients and 80 FR patients.
[0032] 3. Follow the steps of the ELISA kit to conduct subsequent tests. The operation process is as follows:
[0033] (1) After equilibration at room temperature for 60 min, take out the required strips from the aluminum foil bag and seal the remaining strips in a ziplock bag and put them back into the 4°C refrigerator.
[0034] (2) Set up standard wells, blank wells, and sample wells, and add 50 μL of standard of different concentrations to each standard well.
[0035] (3) Add 50 μL of the sample to be tested to the sample well and 50 μL of the sample diluent to the blank well.
[0036] (4) Add 100 μL of horseradish peroxidase (HRP)-labeled detection antibody to each of the blank wells, standard wells, and sample wells, seal the reaction wells with a sealing film, and incubate at 37°C in a constant temperature incubator for 60 min.
[0037] (5) Discard the liquid, pat dry with absorbent paper, add 350 μL of washing solution to each well, let stand for 1 min, shake off the washing solution, pat dry with absorbent paper, and repeat 5 times.
[0038] (6) Add 50 μL of substrate A and B to each well and incubate at 37°C in the dark for 15 min.
[0039] (7) Add 50 μL of stop solution to each well and measure the OD value of each well at a wavelength of 450 nm within 15 min.
[0040] (8) Draw a standard curve based on the OD values of the blank wells and standard wells, and use the standard curve to obtain the protein concentration of the sample. Each sample in the experimental group and the control group was repeated 3 times.
[0041] 4. Statistical methods
[0042] SPSS25.0 statistical software was used for data analysis, and the differences between the two groups were analyzed using t-test or rank sum test. Receiver operating characteristic curve (ROC) analysis was used to determine the diagnostic value of GUCA2A, CCL14, STAB1, and VSIG4 individually and in combination.
[0043] 5. Experimental results
[0044] (1) Proteomic analysis Figure 1 As shown in Figure 2, compared with the ER group, the expression levels of GUCA2A, CCL14, STAB1, and VSIG4 in the FR group at baseline were significantly downregulated, with P GUCA2A =0.00005, P CCL14 =0.005, P STAB1 =0.011, P VSIG4 =0.009.
[0045] (2) The expression of GUCA2A, CCL14, STAB1, and VSIG4 was verified by ELISA in 80 samples in the ER and FR groups, respectively. Figure 2 As shown in Figure 2, it was confirmed that compared with the ER group, the expression levels of GUCA2A, CCL14, STAB1 and VSIG4 in the FR group at baseline were significantly downregulated (P GUCA2A <0.0001, P CCL14 =0.004, P STAB1 =0.025, P VSIG4 =0.006.
[0046] The above verified that the expression levels of GUCA2A, CCL14, STAB1 and VSIG4 in the subjects in the ineffective recanalization group were significantly downregulated at baseline.
[0047] (3) The combined diagnostic performance of differentially expressed proteins GUCA2A, CCL14, STAB1, and VSIG4 was detected by ROC curve analysis and calculation of the area under the ROC curve (AUC). AUC is the area under the receiver operating curve, which is an indicator of diagnostic performance or accuracy. The closer the AUC is to 1, the better the diagnostic performance.
[0048] The experimental results are as follows Figure 3 As shown, the AUC of the predicted probability of the combined diagnosis of proteins GUCA2A, CCL14, STAB1 and VSIG4 was 0.959, 95% CI was 0.923-0.994, P < 0.0001, indicating that GUCA2A, CCL14, STAB1 and VSIG4 can be used as markers for the diagnosis of stroke-related infection.
[0049] The embodiments described above are only some embodiments of the present invention, rather than all embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. The scope of protection of the present invention shall be subject to the scope required by the claims. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work shall fall within the scope of protection of the present invention.
Claims
1. A protein marker combination for screening clinically ineffective recanalization of large vessel occlusive stroke, characterized in that: The protein marker combination includes GUCA2A, CCL14, STAB1 and VSIG4.
2. Use of the protein marker combination as claimed in claim 1 in the preparation of a product for screening clinically ineffective recanalization of large vessel occlusive stroke.
3. The use according to claim 2, characterized in that: The product includes a reagent or a kit for specifically detecting the expression amount of the protein marker combination in a sample.
4. The use according to claim 3, characterized in that: The sample is peripheral blood of the subject.
5. The use according to claim 3, characterized in that: The reagents include human GUCA2A, CCL14, STAB1 and VSIG protein capture antibodies.
6. A kit for screening clinically ineffective recanalization of large vessel occlusive stroke, characterized in that: The invention comprises a detection reagent, wherein the detection reagent comprises human GUCA2A, CCL14, STAB1 and VSIG protein capture antibodies.
7. The kit according to claim 6, characterized in that The kit is an ELISA detection kit.
8. Use of the protein marker combination according to claim 1 in the preparation of a product for diagnosing the prognosis of LVO-AIS patients.
9. The use according to claim 8, characterized in that: The product includes a reagent or a kit for detecting the expression amount of the protein marker combination by ELISA.
Citation Information
Patent Citations
Application of C1QC, VSIG4 and CFD as biomarkers in predicting cardiac stroke caused by atrial fibrillation
CN117116358A
Markers for the diagnosis of large vessel occlusion
US20240192231A1
